Skip to content

Celcuity CELC Less: net unamortized discount

Less: net unamortized discount at other companies

Royalty Pharma logo
Royalty PharmaRPRX

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscount.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's less: net unamortized discount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's less: net unamortized discount?
Celcuity (CELC) reported less: net unamortized discount of $7.92M in Q1 2026.
How has Celcuity's less: net unamortized discount changed year-over-year?
Celcuity's less: net unamortized discount increased by 45.5% year-over-year, from $5.44M to $7.92M.
What is the long-term trend for Celcuity's less: net unamortized discount?
Over 4 years (2021 to 2025), Celcuity's less: net unamortized discount has grown at a 71.9% compound annual growth rate (CAGR), from $962.5K to $8.4M.